Samuel Allen, DO
Pulmonary Disease · Troy, MINPI 1306861414
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $212,460 of the $287,430 with a category attached, or 73.9%. Actelion Pharmaceuticals US, Inc. accounts for 65.5% of it on its own, with 27 other manufacturers making up the rest. Among pulmonary disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 560 payments — averaging $513.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$188K
- United Therapeutics Corporation$42K
- Bayer$34K
- Merck$15K
- AstraZeneca$3K
- Medical Device Business Services, Inc.$2K
- plus $3K from 22 others
Across 46 payments — averaging $2340.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$71K
- Actelion Pharmaceuticals, Ltd$21K
- United Therapeutics Corporation$8K
- Bayer$8K
What the payments were for
- Consulting fees$34,68512%
- Speaking & faculty fees$212,46074%
- Travel & lodging$26,6299%
- Food & beverage$13,3855%
- Education$2710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 203 | $188,237 |
| United Therapeutics Corporation | 56 | $42,260 |
| Bayer | 30 | $33,675 |
| Merck | 19 | $14,926 |
| AstraZeneca | 101 | $2,972 |
| Medical Device Business Services, Inc. | 17 | $1,920 |
| GSK | 47 | $809 |
| Johnson & Johnson(2 entities) | 12 | $450 |
| Insmed, Inc. | 16 | $444 |
| Sanofi | 3 | $348 |
| Verona Pharma, Inc. | 23 | $313 |
| Intuitive Surgical | 1 | $144 |
| Regeneron Healthcare Solutions, Inc. | 3 | $125 |
| Boehringer Ingelheim | 2 | $122 |
| AbbVie | 2 | $111 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $70 |
| Electromed, Inc. | 5 | $66 |
| Gilead | 4 | $55 |
| Pulmonx Corporation | 2 | $55 |
| Mylan Specialty L.p. | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| Sunovion Pharmaceuticals Inc. | 3 | $42 |
| Baxter Healthcare | 1 | $37 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Circassia Inc. | 1 | $18 |
| Sandoz | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$287,430 in reported general payments places this provider in the 95th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 215 | $2,709,057 |
| Tyvaso DpiTreprostinil | 62 | $1,458,522 |
| AdempasRiociguat | 42 | $578,904 |
| LetairisAmbrisentan | 24 | $313,581 |
| UptraviSelexipag | 12 | $282,140 |
| OpsynviMacitentan/Tadalafil | 21 | $271,762 |
| Orenitram ErTreprostinil Diolamine | 12 | $250,506 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 182 | $200,243 |
| Ambrisentan | 17 | $97,980 |
| Tadalafil | 118 | $62,541 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $17,609 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $13,344 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $11,558 |
| EliquisApixaban | 12 | $10,477 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Opsynvi | $188,237 | $3,262,959248 claims |
| BayerAdempas | $33,675 | $578,90442 claims |
| GileadLetairis | $55 | $313,58124 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $809 | $217,852214 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,972 | $15,78326 claims |
| Boehringer IngelheimCombivent Respimat | $122 | $13,34417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Troy
- Marc DunnTroy$16K
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
- Mounir GhaliWyoming$371K
- Kevin FlahertyAnn Arbor$328K
- Podduturu ReddyPort Huron$324K
- Daniel MaxwellAlpena$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.